Improvement By Imeglimin (Twymeeg) In Patient with Type 2 Diabetes (T2D), Cervical Spondylosis and Fatty Liver

Bando H , Okada M, Iwatsuki N, Sakamoto K and Ogawa T

Published on: 2023-05-22

Abstract

Current case is 51-year-old male with type 2 diabetes (T2D). Previous problems included obesity with BMI 35.2 kg/m² and cervical spondylosis treated with baclofen (Lioresal). He was diagnosed as T2D with HbA1c 6.6%, obesity, fatty liver, hyperuricemia, dyslipidemia and chronic kidney disease (CKD). By continuing low carbohydrate diet (LCD), HbA1c was decreased to 5.2% with 6kg weight reduction. UA was 8.3 mg/dL in Jan 2021, and febuxostat was started. HbA1c increased to 6.9% in Oct 2022, and imeglimin (Twymeeg) was started. HbA1c decreased to 5.9% for 6 months. Thus, several medical problems were improved by LCD and imeglimin intake.